Method for producing a conditioned blood composition for treating diseases
By integrating vaccines and specific blood fractions, the method enhances cytokine activation and concentration in conditioned blood compositions, addressing inefficiencies in existing techniques and achieving effective disease treatment with improved interleukin 6 levels and cost-effectiveness.
Patent Information
- Application Number
- PCT/KZ2023/000026
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2023-12-29
- Publication Date
- 2024-11-21
AI Technical Summary
Existing methods for producing conditioned blood compositions for disease treatment, such as those containing cytokines, face inefficiencies in activation rate and cytokine concentration, particularly for interleukin 6, due to mechanical blood processing and lack of sufficient activation.
Incorporating vaccines containing virus fragments, toxins, or weakened microorganism DNA into the blood, along with centrifugation and mixing with leukocyte and platelet-rich blood fractions, and steroid hormones, to enhance cytokine activation and concentration, specifically increasing interleukin 6 levels.
The proposed method significantly increases cytokine concentrations, particularly interleukin 6, achieving higher activation rates and therapeutic efficacy with a cost-effective and easily implementable process, as demonstrated by clinical examples.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001] Method for producing conditioned blood composition for treating diseases
[0002] The invention relates to medicine, to blood-based medicinal products containing induced cytokines for the treatment of human diseases.
[0003] A method is known for producing a conditioned blood composition containing a therapeutically and prophylactically highly effective mixture of biologically active substances, such as cytokines and factors, for example, TNFa, interleukins IL-IRa, IL-6 IL-4, IL-10 IL-13, intended for the treatment of muscle diseases, musculoskeletal system, inflammations and irritations of the nervous system, autoimmune diseases, in particular rheumatoid arthritis, diseases caused by neurodermatitis, as well as for the treatment and healing of chronic wounds, in particular diabetic ulcers, the treatment of endometriosis (patent EAPO 014435, class A61K35 / 14, A61P37 / 00, op. 30.12.2010, patent holder Ortogen AG, DE), prototype.
[0004] The method is carried out as follows. Blood is collected from a patient, incubated in a modified vessel at a temperature of 10-40° for 2-36 hours at a partial oxygen pressure of less than 5 kPa. In this case, the modified vessel has an internal structure with a large surface using, for example, balls, fibers, flour; glass beads can be placed inside the vessel. In an additional stage, cellular components are separated from liquid components by centrifugation and a conditioned blood serum composition is obtained. The composition obtained by this method contains 30-20,000 pg / ml interleukin 6, IL-6, and additional components, for example IL-10, IL-13, insulin-like growth factor PDGF.
[0005] In this method for obtaining a conditioned blood composition, it is proposed to use mechanical action on the blood in the form of making the inner surface of the vessel for processing unsmooth, as well as placing glass beads in the vessel, which does not contribute to sufficiently effective activation of the blood, both in terms of the time of obtaining cytokines and in terms of the concentration of interleukin 6.
[0006] The objective of the proposed invention and the technical result are to develop a method for obtaining a conditioned blood composition for treating diseases, which ensures an increase in the activation rate, as well as a high content of interleukin 6 in the conditioned blood composition. To achieve the technical result in the method for obtaining a conditioned blood composition for treating diseases, which includes collecting the patient's blood, incubating the collected blood in a vessel, centrifuging, according to the invention, the collected patient's blood is mixed with a vaccine containing virus fragments, and / or with a vaccine containing microorganism toxins, and / or with a vaccine with weakened microorganism DNA, after which incubation and centrifugation are carried out to obtain a conditioned blood composition enriched with cytokines.
[0007] In the method for obtaining a conditioned blood composition, the patient's blood taken is mixed with the Vaxigrip influenza vaccine or the Influvac Tetra vaccine, and / or with a vaccine against the hepatitis B virus, and / or with a vaccine against diphtheria and tetanus, and / or with a vaccine against measles, mumps and rubella.
[0008] In the method for obtaining a conditioned blood composition, incubation is carried out at a temperature of 25-40°, preferably at 38°.
[0009] In the method for obtaining a conditioned blood composition, the obtained cytokine-enriched blood composition is mixed with a blood fraction enriched in leukocytes and platelets, obtained by centrifuging blood taken from a patient 6-24 hours after the first blood collection.
[0010] In the method for producing a conditioned blood composition, the cytokine-enriched fraction is mixed with steroid hormones.
[0011] The vaccine used, Vaxigrip (0.5 ml), contains in one dose influenza viruses, inactivated and split, represented by strains equivalent to the following:
[0012] A(HiNi)** 15 mcg GA
[0013] A(Nz N2)** 15 mcg GA
[0014] B** 15 mcg GA
[0015] * the field contains the names of the strains recommended by WHO for the current flu epidemic season.
[0016] ** hemagglutinin.
[0017] One dose of the Influvac Tetra vaccine (0.5 ml) contains hemagglutinin and neuraminidase of the following viral strains:
[0018] A(H3N)** 15 mcg GA
[0019] A(Hi N1)** 15 mcg GA
[0020] B** 15 mcg GA
[0021] * cultivated on chicken embryos of healthy chickens, as well as auxiliary substances.
[0022] The available hepatitis B vaccines are single-antigen vaccines, Engerix-B and Recombivax HB, which contain aluminum adjuvants. The newest formulation, HepB-CpG, uses the immunostimulatory adjuvant cytidine-phosphate-guanosine-oligodeoxynucleotide (CpG-ODN). A combination product combining hepatitis A and hepatitis B vaccines (Twinrix) is also available.
[0023] The measles, mumps and rubella vaccine contains weakened strains of measles, rubella and mumps viruses and excipients: aqueous solution of LS-18, gelatin solution and gentamicin sulfate.
[0024] The diphtheria-tetanus vaccine DPT is an adsorbed combination vaccine that contains killed whole whooping cough bacteria (which is why it is also called whole-cell), diphtheria toxoid (neutralized toxin), and tetanus toxoid.
[0025] In the proposed method for obtaining a conditioned blood composition, blood is activated using the products of the vital activity of bacteria and viruses, while an essential feature of the technology is the use of ready-made vaccine compositions for activation, which increases the activation rate and ensures a high content of interleukin 6 in the conditioned blood composition.
[0026] Carrying out biological activation of blood in comparison with mechanical processing of blood according to the prototype made it possible to obtain a conditioned blood composition with high characteristics of cytokine concentration, as well as to increase the activation rate.
[0027] Mixing the resulting cytokine-enriched blood composition with the leukocyte- and platelet-enriched blood fraction is carried out in the case of, for example, treatment of narrowing of the spinal canal or foraminal canal.
[0028] Mixing the resulting cytokine-enriched blood composition with corticosteroid hormones is carried out in cases, for example, of diseases associated with problems of tendons or lateral ligaments.
[0029] We have compared interleukin 1-1b, interleukin 6 and interleukin 10 in the conditioned blood composition obtained by the proposed method with blood taken from a patient and incubated at 37-38°. It has been determined that in the proposed blood composition, interleukin 1-1b exceeds its usual concentration in plasma by 100 times and the concentration of blood incubated at 37-38° by 10 times. Interleukin 6 exceeds freshly punctured blood by 90 times and heat-treated blood by 5 times, interleukin 10 exceeds normal blood by 10 times and heat-treated blood by 7 times. These data are very important because they allow us to see the difference between normal blood and the conditioned blood composition with the addition of vaccines.
[0030] The proposed method for obtaining a conditioned blood composition is carried out as follows. Using a butterfly needle, a venous puncture is performed and venous blood is collected from the patient in a 10 ml test tube. Then 0.2 ml of the Vaxigrip flu vaccine or the Influvac Tetra vaccine is injected into the test tube with the collected blood using an insulin needle. The test tube is shaken and immersed in a thermostat for 6-24 hours at a temperature of 38° (depending on the amount of desired cytokines). Then centrifugation is carried out at 3500 rpm, and plasma is obtained, separated from dense blood particles. Plasma enriched with cytokines is ready for use in treatment. In the same way, the measles, mumps and rubella vaccine, the hepatitis B virus vaccine, the diphtheria and tetanus vaccine, and mixed vaccines were added to the venous blood.
[0031] 6-24 hours after the first blood collection, a venous puncture is performed and venous blood is collected from the patient in an amount of 5-60 ml. Centrifugation is performed in one, two, or three stages and the blood fraction containing concentrated immune system cells - leukocytes, platelets - is separated and mixed with the resulting cytokine-enriched composition.
[0032] The conditioned blood mixture is mixed with corticosteroid hormones, such as triamcinolone.
[0033] The conditioned blood composition obtained by the proposed method was tested for the treatment of human diseases, but can be used for the treatment of animals, as well as in cosmetology.
[0034] Example 1. A man born in 1981, 41 years old, diagnosis: lateral epicondylitis of the left elbow, complaints: has been suffering for more than 6 months from pain during training with dumbbells in the left elbow, as well as from pain in the left elbow when shaking hands.
[0035] Treatment: one injection of the proposed blood composition enriched with cytokines into the outer condyle of the left humerus. Dynamics: after a month the pains completely disappeared, control, after 6 months the pains did not appear.
[0036] Example 2. A man born in 1986, complaints: has been suffering from pain in the right knee for more than three years, when going up and down stairs. Diagnosis: complete rupture of the posterior horn of the medial meniscus of the right knee joint.
[0037] Treatment: injection of the proposed blood composition mixed with a blood fraction enriched with leukocytes and platelets, using ultrasound control into the posterior horn of the meniscus once a month, twice in total. Dynamics: MRI visualizes the formation of fibrous cartilage at the site of the meniscus tear. The patient noted a complete disappearance of pain when climbing stairs. Example 3. A man born in 1963, 59 years old, diagnosis: plantar fasciitis (heel spur). Complaints: severe pain in both heels, the left more than the right V AS 9 / 10 when stepping in the morning, first steps.
[0038] Treatment: injection of the proposed cytokine-enriched blood composition with the addition of 20 milligrams of triamcinolone.
[0039] Control. After 3 days the pain was completely gone, after 6 months there was no relapse of pain
[0040] Example 4. A woman born in 1950, 72 years old. Complaints: lower back pain radiating to the legs, more than 5 years, noticeable deterioration over the last year, cannot walk independently more than 10, 20 meters and due to radiating pain and weakness in the legs. Diagnosis: stenosis of L4, L5 due to degenerative changes in the spine of about 90-95 percent of the volume.
[0041] Treatment: three injections of the proposed conditioned blood composition, epidurally into the L4, L5 region under MRI control. Each injection was given at intervals of 3-4 weeks.
[0042] Result: A week after the start of treatment, I could walk more than 100 meters, after 6 months I can walk more than a kilometer.
[0043] The proposed method for obtaining a conditioned blood composition for the treatment of diseases provides the following advantages.
[0044] 1. Low price relative to the market, for example, comparing with the blood composition of the prototype - orthokine, the price is about 20 times lower, that is, 20 times cheaper.
[0045] 2. The possibility of creating a cytokine-enriched blood composition corresponding to various treatment goals and activation of immune system response processes in the human or animal body for treatment, restoration, regeneration or cosmetic purposes.
[0046] 3. We have compared interleukin 1-1b, interleukin 6 and interleukin 10 in the conditioned blood composition obtained by the proposed method with blood taken from a patient and incubated at 38°. It has been determined that in the proposed blood composition, interleukin 1-1b exceeds its normal concentration in plasma by 100 times and the concentration of blood incubated at 38° by 10 times. Interleukin 6 exceeds its content in normal blood by 90 times and in heated blood by five times, interleukin 10 exceeds its content in normal blood by 10 times and in heated blood by 7 times.
[0047] 4. Ease of use, simple and inexpensive equipment such as centrifuges and syringes.
[0048] 5. High plasma cytokine concentrations as mentioned in section three.
Claims
Invention formula 1. A method for obtaining a conditioned blood composition for the treatment of diseases, including collecting blood from a patient, incubating the collected blood in a vessel, and centrifuging, characterized in that the collected blood from the patient is mixed with a vaccine containing viral fragments and / or with a vaccine containing microorganism toxins and / or with a vaccine with weakened microorganism DNA, after which incubation and centrifugation are carried out to obtain a conditioned blood composition enriched with cytokines.
2. A method for obtaining a conditioned blood composition according to claim 1, characterized in that the patient's blood taken is mixed with the Vaxigrip influenza vaccine or the Influvac Tetra vaccine, and / or with a vaccine against the hepatitis B virus, and / or with a vaccine against diphtheria and tetanus, and / or with a vaccine against measles, mumps and rubella.
3. A method for obtaining a conditioned blood composition according to claim 1, characterized in that the incubation is carried out at a temperature of 25-40°, preferably at 38°.
4. A method for obtaining a conditioned blood composition according to claim 1, characterized in that the obtained cytokine-enriched conditioned blood composition is additionally mixed with a blood fraction enriched in leukocytes and platelets, obtained by centrifuging blood taken from a patient 6-24 hours after the first blood collection.
5. A method for obtaining a conditioned blood composition according to claim 1, characterized in that the conditioned blood composition enriched with cytokines is additionally mixed with steroid hormones. 6
Citation Information
Patent Citations
Conditioned blood composition and method for its production
EA014435B1
Plasma or serum fraction for the treatment or prevention of bacterial infections
US20060292162A1
Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
WO2010118979A1
